Dawn of a new era in molecular cancer therapeutics
Prog Drug Res
.
2005:63:1-17.
doi: 10.1007/3-7643-7414-4_1.
Author
Richard M Schultz
1
Affiliation
1
Division of Cancer Research, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA. Rick_1252@msn.com
PMID:
16265874
DOI:
10.1007/3-7643-7414-4_1
No abstract available
Publication types
Review
MeSH terms
Animals
Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use*
Drug Design*
Drug Resistance, Neoplasm
Humans
Neoplasms / drug therapy*
Neoplasms / genetics
Patient Selection
Substances
Antineoplastic Agents